Dulaglutide
Evidence: A/E — Established Human EvidenceMetabolic / Weight Management
Evidence Snapshot
What this grade covers
A for the FDA-approved Trulicity finished product's labeled type 2 diabetes and cardiovascular-risk-reduction indications; E for treating any unapproved vendor/research/lyophilized dulaglutide vial as equivalent to Trulicity, and E for any claimed obesity/weight-loss indication.
Regulatory Context
FDA-approved as Trulicity (BLA 125469) for type 2 diabetes glycemic control (adults and pediatric patients 10+) and cardiovascular risk reduction. No FDA-approved obesity/weight-loss indication exists as of the current label reviewed.
Research Takeaway
Dulaglutide is a long-acting GLP-1 receptor agonist fusion protein, FDA-approved as the branded finished product Trulicity for glycemic control in type 2 diabetes (adults and pediatric patients 10 years and older) and for reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors.
Evidence boundary: This approval and evidence base apply to the Trulicity finished biologic product as labeled, not to any unapproved vendor or research dulaglutide material.
See all 4 evidence claims →Quick Summary
Dulaglutide is a long-acting GLP-1 receptor agonist fusion protein, FDA-approved as the branded finished product Trulicity for type 2 diabetes glycemic control and cardiovascular risk reduction. FDA approval applies strictly to the Trulicity finished product -- it does not extend to unapproved vendor, research, or lyophilized dulaglutide material, which is a distinct regulatory and quality category. Dulaglutide/Trulicity does not carry an FDA-approved obesity indication, and semaglutide/tirzepatide outcomes must not be assumed to transfer to it.
Mechanism & Research Overview
Dulaglutide is a GLP-1 receptor agonist consisting of a modified GLP-1 analogue fused to a modified human IgG4 heavy-chain Fc fragment, which extends its half-life for once-weekly dosing. GLP-1 receptor activation stimulates glucose-dependent insulin secretion and suppresses glucagon secretion, supporting glycemic control in type 2 diabetes.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Dulaglutide is a long-acting GLP-1 receptor agonist fusion protein, FDA-approved as the branded finished product Trulicity for glycemic control in type 2 diabetes (adults and pediatric patients 10 years and older) and for reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors.
Does not establish
Evidence boundary: This approval and evidence base apply to the Trulicity finished biologic product as labeled, not to any unapproved vendor or research dulaglutide material.
Sources: TRULICITY (dulaglutide) injection, for subcutaneous use — current FDA-approved Prescribing Information; FDA Approval Letter, BLA 125469 (Trulicity / dulaglutide), original approval
Supported
The current Trulicity label carries a boxed warning for thyroid C-cell tumors based on rodent data and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Does not establish
Evidence boundary: Human thyroid C-cell tumor risk from dulaglutide is unknown; this is a labeled precaution, not a confirmed human outcome.
Supported
No FDA-approved obesity or weight-loss indication exists for dulaglutide/Trulicity as of the label reviewed, and semaglutide or tirzepatide efficacy/safety outcomes must not be transferred to dulaglutide.
Does not establish
Evidence boundary: This is a labeling and evidence-separation statement, not a claim that dulaglutide cannot affect body weight; it addresses only the absence of an approved obesity indication and the risk of cross-molecule evidence transfer.
Supported
FDA's recent compounded-GLP-1 enforcement and safety communications are directed primarily at semaglutide, tirzepatide, and liraglutide; dulaglutide was not identified as a comparable named target of those specific actions in the sources reviewed.
Does not establish
Evidence boundary: Absence from these specific enforcement communications does not establish that unapproved vendor dulaglutide material is safe or high-quality; it is a scoping observation about which molecules those particular FDA communications named.
Sources: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
An unapproved vendor, research, or lyophilized dulaglutide vial is not automatically equivalent to the FDA-approved Trulicity finished product in quality, formulation, or safety.Safety Consideration
Dose-dependent thyroid C-cell tumors were seen in rodent studies; human relevance is unknown. Contraindicated in personal/family history of medullary thyroid carcinoma or MEN 2.Safety Consideration
Do not claim dulaglutide has an FDA-approved obesity indication, and do not transfer semaglutide or tirzepatide efficacy/safety outcomes to dulaglutide.Safety Consideration
Pancreatitis, hypoglycemia (with insulin/secretagogues), hypersensitivity reactions, acute kidney injury, severe GI disease (not recommended, including gastroparesis), diabetic retinopathy complications, and acute gallbladder disease.
Research Areas Being Studied
Research areas discussed on this page reflect the Metabolic / Weight Management category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
No Human Study Findings Listed Yet
See preclinical, regulatory, and review sources below.
Study Tables by Evidence Type
No Sources Listed Yet
Human, preclinical, regulatory, and review sources will appear here as they are added.
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published FDA-approved labeling and does not provide medical advice, a recommendation, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Content pending review. Last updated .
Follow research updates for Dulaglutide
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.